Provided by Tiger Trade Technology Pte. Ltd.

Kairos Pharma, Ltd.

0.2482
+0.01626.98%
Post-market: 0.24820.00000.00%19:46 EDT
Volume:357.44K
Turnover:86.06K
Market Cap:5.88M
PE:-0.89
High:0.2500
Open:0.2425
Low:0.2337
Close:0.2320
52wk High:2.11
52wk Low:0.2200
Shares:23.70M
Float Shares:11.81M
Volume Ratio:0.67
T/O Rate:3.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2781
EPS(LYR):-0.2956
ROE:-113.96%
ROA:-66.91%
PB:1.40
PE(LYR):-0.84

Loading ...

Analysts Offer Insights on Healthcare Companies: Kairos Pharma, Ltd. (KAPA), Integra Lifesciences (IART) and Biogen (BIIB)

TIPRANKS
·
May 14

Kairos Pharma Q1 net loss widens to $1.65 million; no revenue

Reuters
·
May 14

Kairos Pharma announces annual shareholder meeting

Reuters
·
May 09

Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings

THOMSON REUTERS
·
May 09

Analysts Are Bullish on Top Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Actinium Pharmaceuticals (ATNM)

TIPRANKS
·
Apr 03

Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate

Benzinga Earnings
·
Apr 01

Kairos Pharma FY25 net loss widens to $5.4 million; no revenue

Reuters
·
Apr 01

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Pfizer (PFE) and Medtronic (MDT)

TIPRANKS
·
Mar 11

Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy

TIPRANKS
·
Mar 02

Kairos Pharma Signs Binding Deal to Acquire Worldwide Rights to CL-273

Reuters
·
Mar 02

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to Cl-273 From Orbimed and Torrey Pines Investment-Backed Celyn Therapeutics

THOMSON REUTERS
·
Mar 02

Kairos Pharma Ltd - to Buy Cl-273 From Celyn Therapeutics

THOMSON REUTERS
·
Mar 02

BRIEF-Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition

Reuters
·
Feb 26

Kairos Pharma signs term sheet to acquire CL-273 and CL-741 from Celyn Therapeutics

Reuters
·
Feb 26

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets From Celyn Therapeutics

THOMSON REUTERS
·
Feb 26

Kairos Pharma Ltd - to Buy Rights to Cl-273 and Cl-741

THOMSON REUTERS
·
Feb 26